Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Affimed N.V. (AFMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 210,254
  • Shares Outstanding, K 62,390
  • Annual Sales, $ 28,030 K
  • Annual Income, $ -23,000 K
  • 60-Month Beta 3.23
  • Price/Sales 7.77
  • Price/Cash Flow N/A
  • Price/Book 4.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.16
  • Number of Estimates 4
  • High Estimate -0.14
  • Low Estimate -0.19
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.18 +5.97%
on 04/23/19
3.71 -9.16%
on 05/09/19
-0.08 (-2.32%)
since 04/17/19
3-Month
3.18 +5.97%
on 04/23/19
4.68 -27.99%
on 03/20/19
-0.05 (-1.46%)
since 02/15/19
52-Week
1.40 +140.71%
on 08/14/18
7.35 -54.15%
on 08/29/18
+0.94 (+38.97%)
since 05/17/18

Most Recent Stories

More News
Affirmed Therapeutics (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Affirmed Therapeutics (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AFMD : 3.37 (-3.44%)
What's in Store for Affimed (AFMD) This Earnings Season?

Affimed (AFMD) is likely to provide update on the progress of its pipeline candidates when its reports first-quarter results.

AFMD : 3.37 (-3.44%)
MRK : 78.72 (-0.52%)
RHHBY : 32.8400 (+0.71%)
CTST : 5.98 (-1.64%)
Consolidated Research: 2019 Summary Expectations for Frequency Electronics, Quest Resource Holding, Papa John's International, and Affimed N.V -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Frequency Electronics, Inc....

AFMD : 3.37 (-3.44%)
FEIM : 12.04 (+0.25%)
PZZA : 47.82 (-0.73%)
QRHC : 2.45 (+4.26%)
Affirmed Therapeutics (AFMD) Moves to Buy: Rationale Behind the Upgrade

Affirmed Therapeutics (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AFMD : 3.37 (-3.44%)
Implied Volatility Surging for Affimed (AFMD) Stock Options

Investors need to pay close attention to Affimed (AFMD) stock based on the movements in the options market lately.

AFMD : 3.37 (-3.44%)
What Makes Affirmed Therapeutics (AFMD) a New Strong Buy Stock

Affirmed Therapeutics (AFMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

AFMD : 3.37 (-3.44%)
Will Affirmed Therapeutics (AFMD) Report Negative Q4 Earnings? What You Should Know

Affirmed Therapeutics (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AFMD : 3.37 (-3.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade AFMD with:

Business Summary

Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V.,...

See More

Key Turning Points

2nd Resistance Point 3.59
1st Resistance Point 3.48
Last Price 3.37
1st Support Level 3.28
2nd Support Level 3.19

See More

52-Week High 7.35
Fibonacci 61.8% 5.08
Fibonacci 50% 4.38
Fibonacci 38.2% 3.67
Last Price 3.37
52-Week Low 1.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar